Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.…
Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board
Filana Therapeutics (NASDAQ: FLNA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 17 employees.
The shares were at 0.6413 USD on 20 November 2026, down 78.3% over 52 weeks. Its 52-week range is 0.3900 USD to 3.450 USD: the price is 81.4% below the high and 64.4% above the low.
Its market capitalisation is 32.26M USD.
Filana Therapeutics reports return on equity of -122.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 46.99M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 11 March 2027.